A new approval makes Regeneron’s PD-1 blocker the only immunotherapy approved for CSCC after surgery and radiation.
Regeneron's Libtayo gains FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, enhancing ...
When new mother Katelyn Bonacasa developed a bumpy red rash shortly after giving birth, she thought little of it. The spots cleared quickly after a dermatologist visit. But within weeks, far more ...
Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing ...
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...
The combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) with chemotherapy did not help patients with metastatic ...
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.
Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...
Lenvatinib plus pembrolizumab and chemotherapy did not significantly improve overall survival in metastatic ESCC compared to pembrolizumab and chemotherapy alone. Median overall survival was 17.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback